Cargando…

In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019

Aztreonam-avibactam, eravacycline, and cefoselis are three novel antimicrobial agents for the treatment of serious infections caused by Gram-negative bacteria. We evaluated the in vitro activities of the above-mentioned three antimicrobial agents against clinical Enterobacterales isolates. A total o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jiawei, Liu, Yong, Jia, Wei, Xu, Xuesong, Sun, Guizhen, Wang, Tong, Li, Jin, Zhang, Ge, Jing, Ran, Sun, Hongli, Xu, Yingchun, Liu, Yali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269566/ https://www.ncbi.nlm.nih.gov/pubmed/37184411 http://dx.doi.org/10.1128/spectrum.04873-22

Ejemplares similares

Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistance
por: Wu, Shikai, et al.
Publicado: (2022)

Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales
por: Kelley, C. J., et al.
Publicado: (2022)

In vitro and in vivo Antimicrobial Activities of Ceftazidime/Avibactam Alone or in Combination with Aztreonam Against Carbapenem-Resistant Enterobacterales
por: Lu, Guoping, et al.
Publicado: (2022)

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)
por: Sader, Helio S, et al.
Publicado: (2023)

Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
por: Sun, Shan, et al.
Publicado: (2022)

In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant Enterobacterales Isolates from South Korea
por: Kim, Taeeun, et al.
Publicado: (2020)

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
por: Bae, Moonsuk, et al.
Publicado: (2021)

In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
por: Wang, Wen, et al.
Publicado: (2021)

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020
por: Bhatnagar, Amelia, et al.
Publicado: (2021)

2146. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)
por: Sader, Helio S, et al.
Publicado: (2023)

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing bla(KPC) or bla(NDM)
por: Kuai, Junyang, et al.
Publicado: (2023)

2755. Activity of Aztreonam-avibactam and Carbapenem-resistant Enterobacterales (CRE) Isolates Collected in a Six-year Period (2017–2022)
por: Castanheira, Mariana, et al.
Publicado: (2023)

1252. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Bloodstream Infections collected during the ATLAS Global Surveillance Program, 2015-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

In vitro activity of aztreonam–avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019–2021
por: Wise, Mark G., et al.
Publicado: (2023)

2747. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-β-Lactamase-Producing Enterobacterales collected through the Antimicrobial Resistance Laboratory Network, March 2019 to April 2023
por: Bhatnagar, Amelia, et al.
Publicado: (2023)

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope
por: Taha, Rawan, et al.
Publicado: (2023)

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria
por: Emeraud, Cécile, et al.
Publicado: (2023)

1225. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales Collected from Geriatric Patients in ICU and non-ICU wards, ATLAS Surveillance Program 2016-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

Correction: Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope
por: Taha, Rawan, et al.
Publicado: (2023)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Yu, Wei, et al.
Publicado: (2021)

1231. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Lower Respiratory Tract Infections Collected During the ATLAS Global Surveillance Program, 2017-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

1567. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Multidrug-Resistant Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2016-2018
por: Kazmierczak, Krystyna, et al.
Publicado: (2020)

2149. In vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant Enterobacterales With and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021
por: Wise, Mark G, et al.
Publicado: (2023)

1949. Activity of Aztreonam-Avibactam against Enterobacterales Resistant to Recently Approved Beta-Lactamase Inhibitor Combinations Collected Worldwide (ex-US; 2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

A Simple Disk Stacking Plus Micro-Elution Method for Rapid Detection of the Synergistic Effect of Aztreonam and Ceftazidime/Avibactam Against Metallo-β-Lactamase Producing Enterobacterales
por: Liu, Zhou, et al.
Publicado: (2023)

Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter
por: Wu, Shikai, et al.
Publicado: (2023)

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2021)

1717. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2020
por: Estabrook, Mark, et al.
Publicado: (2022)

2119. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2021
por: Estabrook, Mark, et al.
Publicado: (2023)

2756. Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021)
por: Castanheira, Mariana, et al.
Publicado: (2023)

Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era
por: Bianco, Gabriele, et al.
Publicado: (2022)

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020
por: Piérard, Denis, et al.
Publicado: (2023)

In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
por: Zou, Chunhong, et al.
Publicado: (2020)

1422. Comparative Monte-Carlo Analysis of Aztreonam-Avibactam vs. Ceftazidime–Avibactam Against Carbapenem-Resistant Gram-Negative Pathogens
por: Smith, Aaron, et al.
Publicado: (2018)

1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
por: Sader, Helio S, et al.
Publicado: (2022)

Performance Evaluation of the Gradient Diffusion Strip Method and Disk Diffusion Method for Ceftazidime–Avibactam Against Enterobacterales and Pseudomonas aeruginosa: A Dual-Center Study
por: Zhang, Jingjia, et al.
Publicado: (2021)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro
por: Lin, Qiuxia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_371vf8fkteidisjeperakdgrcj